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ABSTRACT

The Center for Disease Control approximates that one out of every four women carries
Group B Streptococcus (GBS) bacteria. GBS can be passed to the neonate from the
pregnant mother during vaginal delivery or in utero by the ascending route1. Some
notable diseases that are caused by GBS are sepsis, meningitis, pneumonia, certain skin
infections, and types of bone and joint infections2. One of the most important virulence
factors for GBS is capsule, which has sialic acid residues attached to the polysaccharide
chains helping to prevent the host immune system from being triggered when the
pathogen is present. CpsA is a protein found in Streptococcus agalactiae, GBS, that plays
a role in production and ligation of the capsule to the cell wall. This research aims to
understand the mechanisms used by the CpsA protein to create and attach the capsule.
Previous research in this lab has specifically focused on the two aspartic acid residues in
the metal binding site of CpsA. This research showed that changing negatively charged
aspartic acid residues to a different neutral amino acid resulted in decreased capsule
expression. To continue the experiment, this project will be focusing on the third residue
within this metal binding domain, arginine, and mutating it to an alanine. Some
hypothesized results include that the mutation will cause less capsule production or
attachment, increased resistance in zebrafish, and a possible difference between the single
mutation compared to the double mutation in the metal binding site.
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INTRODUCTION

Group B Streptococcus
The Center for Disease Control approximates that one out of every four women
carries Group B Streptococcus (GBS) bacteria. For an opportunistic pathogen, this
bacteria can inhabit the vaginal tract and other areas on the body without causing any
harm for the host with a healthy immune system. However, this bacteria has a 55%
mortality rate in infected newborns3 as well as high mortality rates in the elderly and
other immunocompromised people. GBS can be passed to the neonate from the pregnant
mother during vaginal delivery or in utero by the ascending route1. Intrapartum antibiotic
prophylaxis is currently the only way to aid in prevention of transferring of GBS bacteria
from mother to neonate. However, there are a number of complications that are
associated with the procedure, including increased resistance to antibiotics as well as
possible negative long term effects on the neonate as well as possible effects on the
mother’s gut microbiota4.
Neonates experience both early onset and late onset disease types. Early onset
disease occurs within the first week of a baby’s life, whereas late onset is categorization
by the disease occurring after the first week until the end of the first three months of
life2,5,6. Both early and late onset cause similar infections such as sepsis, bacteremia,
pneumonia, and meningitis, with meningitis being more commonly associated with late
onset GBS.
Immunocompromised adults, as well as, the elderly are also specific populations
that are at risk for GBS disease, though are at a lower risk than newborns4. Many of the
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diseases that occur in affected neonates are the same as diseases that occur in adults, such
as sepsis, meningitis, pneumonia, certain skin infections, and types of bone and joint
infections1. If the mechanisms of pathogen infection can be better understood, more
targeted drug therapies can be created to more effectively prevent these diseases,
including the development of a specific vaccination.
Group B Streptococcus is a Gram positive bacterium, which means that this
bacteria has a thicker outer cell layer compared to Gram negative bacteria. In GBS
specifically, there is a capsule around the cell, exterior to the thick outer cell wall7. This
capsule helps to prevent the immune system of the host from being triggered when the
pathogen is present8. The capsule also specifically allows for the bacteria to survive in the
bloodstream. Usually the immune system is activated early by any unknown pathogen
and the macrophages and neutrophils can phagocytose the bacteria. However, the capsule
inhibits phagocytosis by the immune cells. The mechanism for this inhibition is the
production of sialic acid molecules on the capsule that are the same as those found on our
cells9,10. Therefore, this bacteria looks like self and is not recognized by the host immune
system. Without the immune system being triggered, the bacteria can grow, multiply, and
colonize the host without intervention.
CpsA is a protein found in GBS that that plays a role in production and ligation of
the capsule to the outer cell wall8. Knowledge gained about the functions of the CpsA
protein is key for understanding the mechanisms used to create and attach the capsule to
the cell wall. Using this information may allow new therapeutic strategies that could
target the CpsA protein and cause the bacteria to be less virulent. If the bacteria was less
virulent, the immune system would be able to better detect and kill the invading
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pathogen. This would potentially enable physicians to prescribe a medication that is not
an antibiotic and help prevent development of antibiotic resistance that is becoming an
increasing issue.
CpsA Structure
CpsA is a membrane protein, with three transmembrane regions, and two
extracellular domains, the accessory domain and the LytR domain (Figure 1).
Figure 1

Figure 1. Topology of CpsA Protein Showing intracellular and Extracellular Domains.

The role of CpsA has been determined as an activator of transcription and capsule
production9,11. Not only is the CpsA protein highly conserved in different GBS strains but
is also found in Streptococcus pneumoniae and Streptococcus iniae. There is
approximately 70% conservation between GBS and S. pneumoniae (Figure 2).
Figure 2

Figure 2. Amino Acid Sequence of GBS and S. pneumoniae. The top sequence is GBS and the bottom is S.
pneumoniae. The highlighted letter is the amino acid that was mutated in this research. The asterisks indicate the same
amino acid, the colon indicated similar amino acids.

This protein is closely associated with capsule production as results have shown that
when the protein is deleted, a significant reduction in capsule was present9,12. This nonpolar deletion did not affect any proteins downstream from the deletion site. However,
CpsA has been shown to be multifunctional as it has a role in cell wall integrity, DNA
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binding, inhibition of complement, and enzymatic roles as well as its role with capsule
activation9,11.
Previous Research
Previous work demonstrated that CpsA can regulate and activate transcription13.
This protein is closely associated with capsule production as results have shown that
when the protein is deleted, a significant reduction in capsule was present8,11. This nonpolar deletion did not affect any proteins downstream from the deletion site. However,
CpsA has been shown to be multifunctional as it has a role in cell wall integrity, DNA
binding, inhibition of complement, and enzymatic roles among its role with capsule12.
While still being studied, there is a lot about this protein that is not known, specifically
the mechanism of how it regulates capsule production.
Kawai et al performed various studies on this protein in S. pneumoniae in 201111.
The main goal of this study was to identify regions on the Cps2A protein that were
significant in function. Cps2A is the analogous protein to GBS CpsA that is found in S.
pneumoniae. The two major extracellular domains found within the protein are the
accessory domain and the Lyt-R domain. These domains fold completely independently,
therefore indicating separate functions11. There is a peptide loop that connects the two
domains together, however this area was unable to be assigned a structure. The
movement and variability in this region prevented a particular folding pattern from being
identified. Kawai et al’s research showed what specific connections were seen to be
important in the Lyt-R region. The crystal structure of this domain was found to have a
buried lipid molecule, leading them to suggest that it may be acting as the ligase that
enzymatically ligates the capsule to the cell wall. The capsule structure starts as
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monosaccharides on the intracellular leaflet of the membrane. Then, the enzyme flippase
allows the capsule to be flipped extracellularly, where polymerases add polysaccharides
to grow chain and finally a ligase enzyme attaches the capsule to the peptidoglycan
layer6,7.
The Kawai et al study solved the crystal structure of the protein and was able to
use that data to then identify certain amino acid residues that could be most prominent in
capsule production and attachment. One such area located was a magnesium metal
binding site (Figure 3). This site is an

Figure 3

area of three amino acids, two aspartic
acid (D234, D246) and one arginine
(R267), that bind to a magnesium metal
ion and activates an enzyme catalysis
site. However, GBS is used for this
research project and the analogous
Figure 3. Metal Binding Structure of S. agalactiae.
R267A is shown with blue carbons.

residues are in slightly different

positions. The three key residues for metal binding in GBS are D238, D250, and R278.
Previous research in the Neely lab has specifically focused on the two aspartic
acid residues in the metal binding pocket14. This research showed that changing negative
aspartic acid residues to a different neutral amino acid resulted in decreased capsule on
the cell. To continue the

Figure 4

analysis, this project focused
on the third residue, arginine
(R) and mutated it to be an

Figure 4. Amino Acid Sequence of Group B Strep. Wild Type sequence
(top) and Mutated sequence (bottom).
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alanine (A). The mutation was created independently from the previous mutations of the
aspartic acids. Arginine is a positively charged amino acid and alanine is neutral. The
location in GBS of the arginine that was mutated is R271 (Figure 4).
Research Goals
The main goal of this experiment is to have a more mechanistic understanding of
the CpsA protein. This was accomplished by creating create a point mutation to
determine how GBS is affected by the mutation and analyze the effects of the constructed
mutant strain on virulence. The hope is that this information could aid researchers in
synthesizing new medications that decrease bacterial virulence by promoting the immune
system’s normal functions.
The zebrafish infectious disease model was used as these fish have similar
immune systems to humans. During their early stages of development, zebrafish only
have innate immunity, which is when injections of GBS strains for this research will be
done. Sine the infections to zebrafish larvae are acute infections, only innate immunity
plays a role. The experiment will look at acute infections, which entails determining
zebrafish survival over three days without adaptive immunity playing a role. Zebrafish
are still transparent at the larva stage of development and can be easily observed
internally under a microscope. Infections will be injected into the yolk sac. This type of
injection is similar to intraperitoneal characteristics of humans as well as being an easier
target for injection.
Some hypothesized results are the mutation will cause less capsule production or
attachment, an increase in chain length, and decreased virulence in zebrafish. Since the
original arginine is a positively charged molecule, the same change as the magnesium ion
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that fits in this binding pocket, there might not be as great of a phenotypic change with
mutating the residue to alanine, a neutral molecule. The previous findings showed that
mutating the two aspartic acids resulted in increased chain length and decreased capsule.
The arginine in this pocket is proposed to help coordinate the two aspartic acid residues
in the correct conformation to hold the magnesium ion11.These findings are consistent
with previous studies on CpsA mutations.
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METHODS

Mutant Strain Construction
The plasmid pLZ12-rofA-pro (strain # 12E34) was digested with PstI and BamHI.
Polymerase Chain Reaction was performed using GBS, strain 515 chromosome as
template. The primers used for the first reaction were 5’ GBS-CpsA-RBS-BamHI and 3’
CpsA-R271A. This reaction created an 810 base pair fragment with the R271A single
mutation. The primers used for the second reaction were 5’ CpsA-R271A and 3’GBSCpsA-full-PstI. This reaction created a 650 base pair fragment, also including the
mutation. The fragments were then gel isolated to purify the fragments away from the
chromosomal DNA and to confirm sizes. The splice overlap extension reaction (PCRSOE) was used to combine both fragments with the mutation using primers 5’ GBSCpsA-RBS-BamHI and 3’GBS-CpsA-full-PstI (Figure 5). This created a full size
fragment of 1470 base pairs containing the mutation. The whole fragment was gel
purified and the correct size was confirmed. The fragment was then digested with BamHI
and PstI. The digested fragment was then ligated into the digested vector, followed by
transformation into competent E. coli by electroporation. Plasmid DNA was isolated
from transformants and sequenced to confirm the mutation was in the correct position
and that there were no other mutations in the rest of the cpsA gene. Plasmids showing the
correct sequence were then transformed into the WT GBS strain and the ΔcpsA GBS
strain.
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Figure 5

Figure 4. PCR SOEing Reaction. The single amino acid mutation was made
through a combination of three reactions.

Enzyme-linked immunosorbent assay (ELISA)
The ELISA was used to quantitatively determine the amount of capsule present on the
cell surface of each strain. Overnight cultures were grown in 10 mL of Todd-Hewitt
Yeast Broth (THY-B) and 3ug/ml chloramphenicol. The secondary antibody was
preabsorbed with 2.5 mL of a mixture of the WT and ΔCpsA cultures for 1 hour and filter
sterilized. The overnight cultures were normalized to an OD600 of 0.75 and incubated
with a 1:20,000 dilution of primary antibody (rabbit anti-serotype 1a) for 1 hour at 4˚C.
After 3 washes in Tris-buffered saline + 0.1% Tween (TBST), the cultures were
incubated with secondary antibody (Goat anti-rabbit IgG conjugated to alkaline
phosphatase) for 1 hour at 4˚C. Negative controls were the WT and ΔCpsA strains that
were only incubated with the secondary antibody and not the primary. After 3 final
washes in TBST, a liquid alkaline phosphatase assay was performed on all reactions in
triplicate at no dilution, 1:2, and 1:4. The results were read at OD405 and OD600.

Cell Morphology
Overnight cultures were grown in 5 mL of THY-B and 3ug/ml of chloramphenicol. Six
microliters of each strain were placed on a slide and observed under the compound
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microscope at 1000X. Ten fields of view were photographed for each strain. Chain length
was counted and analyzed for mean and mode and compared to other groups.
Virulence Assays
To determine survival of zebrafish larvae infected with each strain, virulence assays were
performed. Two day old dechorionated zebrafish larvae were used for virulence assays.
Overnight cultures were grown in 5 mL of THY-B and 3ug/ml chloramphenicol,
subcultured the next morning and grown to 1x108 CFU/mL. Yolk sac injection were
performed with all strains at a dose if 100 CFU. Inoculum was confirmed by plating on
agar plates. After all injections completed, the fish incubated at 27-29°C and monitored
for three days post infection. Survival curve data was taken at 24, 48, and 72 hours post
infection.
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RESULTS

Morphology
Observation of the Wild Type GBS strain with an empty plasmid indicates that
the average number of cocci per chain (i.e. chain length) is between one and two cocci
(Figure 6). When compared to the ΔCpsA strain with empty plasmid, the Wild Type
strain with empty plasmid exhibits much lower average chain length (Figure 6, columns
1,3). This is further seen when comparing the frequency of cocci per chain between the
two strains (Figures 7 and 8). The Wild Type strain with empty plasmid has the highest
frequency of chain lengths between one and three cocci whereas the ΔCpsA strain with
empty plasmid has frequencies ranging from two to four cocci per chain all the way to
thirty to thirty-two cocci per chain (Compare Figure 7 to Figure 8).
When a plasmid expressing the Wild Type cpsA is added to the Wild Type GBS
strain, the chain length is slightly decreased even more compared to the Wild Type strain
with empty plasmid (Figure 6, columns 1 and 2). With the ΔCpsA strain with empty
plasmid showing a much greater average number of cocci per chain, the ΔCpsA strain
with Wild Type cpsA plasmid complements the phenotype back to Wild Type strain with
empty plasmid chain length levels (Figure 6, column 4). This indicates that adding the
Wild Type cpsA plasmid allows for relatively normal morphology expression.
The Wild Type strain with cpsA mutant plasmid shows the same number of cocci
per chain as the Wild Type strain with Wild Type cpsA plasmid (Figure 6, columns 4 and
5). The ΔCpsA strain with cpsA mutant plasmid shows a similar average number of cocci
per chain as the ΔCpsA strain with empty plasmid (Figure 6, compare column 3 and 4).
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While the ΔCpsA strain with cpsA mutant plasmid does not complement the phenotype
completely back to ΔCpsA strain with empty plasmid levels, there is a significant
increase from the ΔCpsA strain with Wild Type cpsA plasmid levels (Figure 6, columns
3, 5, 6). This is further seen by the frequency of the number of cocci per chain in the Wild
Type with cpsA Mutant Plasmid to be only between one and three (Figure 9). This is
similar to the frequencies seen of the Wild Type with empty plasmid strain. The ΔCpsA
with cpsA Mutant Plasmid still has a high frequency of short chain lengths ranging
between one and three, but it also has a broader range of cocci per chain as well as higher
frequency of longer chains with nine to eleven cocci (Figure 10).
Figure 6

Figure 6. Number of Cocci per Chain Comparison. Six microliters of each strain type were placed on a
slide and ten fields of view were imaged. The number of cocci per chain were counted. Error bars represent
Standard Error of the Mean. Minimum N = 201. The number of cocci per chain were counted manually.
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Figure 7

Figure 7. Wild Type with Empty Plasmid Frequency of cocci per chain. The
most frequent number of chain lengths was between one and three.

Figure 8

Figure 8. ΔCpsA with Empty Plasmid Frequency of cocci per chain. The most frequent
number of cocci per chain length was between one and four, however there was also an increased
number of chains with greater than ten cocci per chain, which is not seen in the Wild Type strains.

13

Figure 9

Figure 9. ΔCpsA with cpsA Mutated Plasmid Frequency of number of cocci
per chain counts. The chains most frequently had between one and three cocci
with not chains having more than five cocci.

Figure 10

Figure 10. ΔCpsA with cpsA Mutant Plasmid Frequency of number of cocci per chain.
The highest frequency of cocci per chain was between one and four. This strain also had an
increased number of chains with frequencies higher than ten, with chain lengths up to
twenty-eight cocci.
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ELISA

In the ELISA, alkaline phosphatase units directly correlate with the amount of
serotype 1a capsule on the GBS cell surface. The Wild Type strain with empty plasmid
showed the highest amount of alkaline phosphatase (AP) units at 6910 (Figure 11). The
lowest amount of alkaline phosphatase units was the ΔCpsA strain with empty plasmid,
5407 AP units. The Wild Type strain with cpsA mutant plasmid showed a decrease in
capsular expression when compared to the Wild Type strain with empty plasmid but
increased when compared to the ΔCpsA strain with empty plasmid. The ΔCpsA strain
with the mutant cpsA plasmid is seen to almost fully complement capsular levels back to
that of the Wild Type strain with empty plasmid. The ΔCpsA strain with cpsA mutant
plasmid shows a greater than 1,200 AP UNITS increase in capsule when compared to the
ΔCpsA strain with empty plasmid.
Figure 11
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Figure 11. ELISA Polysaccharide Capsule Comparisons. Adjusted averages are shown. These
are calculated through subtracting
the background
values of the Wild Type and ΔCpsA. Error
Zebrafish
Infections
bars represent the Standard Error of the Mean.

When zebrafish are injected with a negative control (sterile media), there is close
to 100% survival rate 72 hours post infection (Figure 12). When injected with the Wild
Type strain with empty plasmid, there is almost 80% death 72 hours post infection. The
fish injected with the ΔCpsA strain with empty plasmid are seen to have around 90%
death. Zebrafish injected with the ΔCpsA with cpsA mutant plasmid are seen to have
around 80% death at 72 hours post infection, similar to the percentage survival of the
Wild Type strain with empty plasmid. The ΔCpsA strain with cpsA mutant plasmid also
shows survival levels similar to the negative control infection at 24 hour post infection,
but sharply drops to 50% at 48 hours post infection (Figure 12).

16

Figure 12

Figure 12. Survival Curve in Zebrafish Comparison. Zebrafish were infected with either a negative
control of THY-B, and Wild Type with Empty Plasmid, ΔCpsA with Empty Plasmid, or ΔCpsA strain with
Mutant Plasmid. Fish were observed at 24, 48, and 72 hours post infection. Data are representative of two
trials, each of 20 fish.

DISCUSSION

Chain length, polysaccharide expression, and virulence were examined to assess
the effect an amino acid change in the CpsA protein sequence. Through comparisons to
the normal Wild Type strain with empty plasmid and ΔCpsA strain with empty plasmid,
the specific changes that occur were analyzed. Analysis of the effects of mutational
changes may provide a greater degree of understanding of GBS as a pathogen and what
specific residues play key roles in its virulence.
Colony Morphology
The Wild Type strain with cpsA mutant plasmid has similar chain lengths to the
Wild Type strain with empty plasmid, this means that the mutation did not affet chain
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length in the Wild Type strain (Figure 6). In comparing the frequency of the number of
cocci per chain, this remains consistent between the Wild Type strain with cpsA mutant
plasmid and the Wild Type strain with empty plasmid (Figures 7 and 9). Therefore, there
is not a dominant negative effect when adding the mutated form of cpsA into the Wild
Type strain.
However, when the mutant plasmid is added to the ΔCpsA strain, there is
complementation back to similar levels of the ΔCpsA strain with empty plasmid (Figure
6). This complementation can also be seen in the frequency of number of cocci per chain
between both ΔCpsA strains (Figures 8 and 10). Although, the mutation to the one amino
acid does not cause chain lengths to be as high as ΔCpsA strain with empty plasmid, it
does indicate that the single mutation does have an effect.
ELISA
Capsule expression in the Wild Type strain with cpsA mutant plasmid shows a
slight decrease when compared to the Wild Type strain with empty plasmid. This
indicates that the mutated plasmid could have a dominant negative effect on the Wild
Type strain when observing the amount of capsule on the cell. The ΔCpsA strain with
mutant plasmid shows a much greater amount of capsule compared to the ΔCpsA with
empty plasmid. This indicates that adding the mutated plasmid into the ΔCpsA strain
brings back capsule expression back to a level that is more consistent with Wild Type
strain values. When compared to the results of the number of cocci per chain, the
variability shows that the single mutation causes an intermediate phenotypic expression.
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Zebrafish Infections
Using the zebrafish model of infectious disease, zebrafish survival after infection
was observed when comparing different strains of Group B Streptococcus 515. The
results indicate the one mutation of arginine to alanine in the metal binding region of the
Lyt-R domain does not cause a significant decrease in virulence. Instead, a similar
percentage of survival was observed for the ΔCpsA strain with the mutant cpsA plasmid
as the wild type strain (Figure 12).
One hypothesized reason for these results is the type of mutation that was made
may not have been different enough to cause a significant effect using the assays in this
project. Arginine is a positively charged, aliphatic amino acid whereas alanine is a
nonpolar, aliphatic amino acid. The magnesium metal binding triad consists of two
negatively charged aspartic acids and one arginine. Previous research involved mutating
the two aspartic acids to alanine indicated that this change caused an increase in number
of cocci per chain as well as a decrease in polysaccharide capsule expression. The
arginine in this metal binding pocket has been shown to coordinate the two aspartic acids
that complete the triad11. Thus, the arginine amino acid does not directly interact with the
magnesium molecule. This indirect relation could be the reason that the mutation to the
arginine residue in this research does not have a profound impact on the binding ability of
the metal ion. In Wild Type strains, only the two aspartic acids are directly affecting the
placement of the magnesium ion while the arginine stabilizes the transition state. When
mutated to alanine, there was variable results since there was no effect on the other two
residues in the metal binding pocket. Because of this, the binding ability to the
magnesium metal was not directly affected, only the coordination and stability of the
arrangement. This issue in stability could explain why the results were variable.
19

Future Directions
Subsequent trials are needed to replicate the results and ensure greater statistical
significance. The ELISA should be performed again for further validation. The zebrafish
injections should also be repeated as there is a possibility of contamination in the ΔCpsA
strain with the ΔcpsA mutant plasmid as well as mutations caused by the age of the adult
zebrafish bred from.
Further research to be completed would be combining the two aspartic acid
mutations with the one arginine mutation, thus mutating all three of the amino acids in
the magnesium metal binding region. This would aid in determining the direct and
holistic effects the magnesium binding has on capsule production, ligation, and colony
morphology. With the removal of the entire metal binding site, these results could show a
higher degree of decreased capsule production. The two aspartic acids were not tested for
virulence in the zebrafish model, this research should be conducted in the future.
Additional zebrafish infection trials should be completed with various inoculums. In
previous research, adult zebrafish were used compared to the two day old fish that were
used in this study. There is a possibility that the 100 CFU dose of bacteria was too much
for the age of fish that were used and could have caused the results to not accurately
depict the virulence of the bacteria. Subsequent trials should perform the infections using
a lower dose of 10 CFUs instead. More infection trials should also be done so neutrophil
recruitment can be observed in order to identify immune system responses to the bacterial
infection.
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